A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia

Nature Biotechnology

Volumn 29, Issue 11, 2011, Pages 1028-1033

  Ivanciu, Lacramioara ^a   Toso, Raffaella ^a   Margaritis, Paris ^a,b   Pavani, Giulia ^a   Kim, Haein ^a   Schlachterman, Alexander ^a   Liu, Jian Hua ^a   Clerin, Valerie ^c   Pittman, Debra D ^c   Rose Miranda, Rosalind ^c   Shields, Kathleen M ^c   Erbe, David V ^c   Tobin, James F ^c   Arruda, Valder R ^a,b   Camire, Rodney M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOT FORMATION; CLINICAL CONDITIONS; COAGULATION FACTOR; COFACTORS; EFFECTIVE THERAPY; FACTOR XA; IN-VIVO; MOUSE MODELS; VASCULAR INJURY; WILD TYPES;

DEFECTS; MAMMALS;

COAGULATION;

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10AI16L; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; ENZYME PRECURSOR; PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; HEMOPHILIA; HEMOSTASIS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; ENZYME PRECURSORS; FACTOR VIIA; FACTOR XA; GENE EXPRESSION; HEK293 CELLS; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HEMOSTATICS; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; THROMBIN;

ANIMALIA; MURINAE;

EID: 80755125572     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1995     Document Type: Article

References (36)

1. Toso, R., Zhu, H. & Camire, R.M. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly. J. Biol. Chem. 283, 18627-18635 (2008).
2. Bunce, M.W., Toso, R. & Camire, R.M. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro. Blood 117, 290-298 (2011).
3. Hedner, U. Mechanism of action, development and clinical experience of recombinant FVIIa. J. Biotechnol. 124, 747-757 (2006). (Pubitemid 44066599)
4. Roberts, H.R. & Ma, A.D. Overview of inherited hemorrhagic disorders. in Hemostasis and Thrombosis: Basic Principles and Clinical Practice. (eds. Colman, R.W., Marder, V.J., Clowes, A.W., Gerorge, J.N. & Goldhaber, S.Z.) 877-885 (Lippincott Williams & Wilkins, Philadelphia, 2006).
5. Mann, K.G., Nesheim, M.E., Church, W.R., Haley, P.E. & Krishnaswamy, S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76, 1-16 (1990). (Pubitemid 20220784)
6. Mannucci, P.M. Back to the future: a recent history of haemophilia treatment. Haemophilia 14 (suppl. 3), 10-18 (2008). (Pubitemid 351722377)
7. DiMichele, D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br. J. Haematol. 138, 305-315 (2007).
8. Darby, S.C. et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-1999. J. Thromb. Haemost. 2, 1047-1054 (2004).
9. Turecek, P.L., Varadi, K., Gritsch, H. & Schwarz, H.P. FEIBA: mode of action. Haemophilia 10, 3-9 (2004).
10. Berntorp, E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 15, 3-10 (2009).
11. Escobar, M.A. Health economics in haemophilia: a review from the clinician's perspective. Haemophilia 16 (suppl. 3), 29-34 (2010).
12. Monroe, D.M., Hoffman, M., Oliver, J.A. & Roberts, H.R. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br. J. Haematol. 99, 542-547 (1997). (Pubitemid 27519853)
13. Butenas, S., Brummel, K.E., Bouchard, B.A. & Mann, K.G. How factor VIIa works in hemophilia. J. Thromb. Haemost. 1, 1158-1160 (2003).
14. Gitel, S.N., Medina, V.M. & Wessler, S. Inhibition of human activated Factor X by antithrombin III and alpha 1-proteinase inhibitor in human plasma. J. Biol. Chem. 259, 6890-6895 (1984). (Pubitemid 14078986)
15. Giles, A.R., Nesheim, M.E. & Mann, K.G. Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation. J. Clin. Invest. 74, 2219-2225 (1984). (Pubitemid 15197367)
16. Giles, A.R., Mann, K.G. & Nesheim, M.E. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br. J. Haematol. 69, 491-497 (1988).
17. Khan, A.R. & James, M.N.G. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 7, 815-836 (1998). (Pubitemid 28216525)
18. Bode, W. et al. The refined 1.9 Å crystal structure of human α-thrombin: Interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Trp insertion segment. EMBO J. 8, 3467-3475 (1989). (Pubitemid 19273577)
19. Tchaikovski, S.N., van Vlijmen, B.J., Rosing, J. & Tans, G. Development of a calibrated automated thrombography based thrombin generation test in mouse plasma. J. Thromb. Haemost. 5, 2079-2086 (2007). (Pubitemid 47450027)
20. Schlachterman, A. et al. Factor V Leiden improves in vivo hemostasis in murine hemophilia models. J. Thromb. Haemost. 3, 2730-2737 (2005). (Pubitemid 41819802)
21. Turecek, P.L. et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol. Haemost. Thromb. 33, 16-22 (2003). (Pubitemid 37449291)
22. Aljamali, M.N. et al. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J. Clin. Invest. 118, 1825-1834 (2008). (Pubitemid 351632385)
23. Margaritis, P. et al. Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo. Blood 117, 3974-3982 (2011).
24. Weeterings, C., Lisman, T. & de Groot, P.G. Tissue factor-independent effects of recombinant factor VIIa on hemostasis. Semin. Hematol. 45, S12-S15 (2008). (Pubitemid 351787689)
25. Monroe, D.M., Hoffman, M. & Roberts, H.R. Platelets and thrombin generation. Arterioscler. Thromb. Vasc. Biol. 22, 1381-1389 (2002).
26. Tranholm, M. et al. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A. Blood 102, 3615-3620 (2003). (Pubitemid 37409379)
27. Petersen, L.C. et al. Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study. Thromb. Res. 116, 75-85 (2005). (Pubitemid 40546328)
28. Tracy, P.B., Eide, L.L., Bowie, E.J.W. & Mann, K.G. Radioimmunoassay of factor V in human plasma and platelets. Blood 60, 59-63 (1982). (Pubitemid 12085920)
29. Moss, J., Scharling, B., Ezban, M. & Moller, S.T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J. Thromb. Haemost. 7, 299-305 (2009).
30. Weiler-Guettler, H. et al. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J. Clin. Invest. 101, 1983-1991 (1998). (Pubitemid 28226118)
31. Neyman, M., Gewirtz, J. & Poncz, M. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots. Blood 112, 1101-1108 (2008).
32. Lin, H.F., Maeda, N., Smithies, O., Straight, D.L. & Stafford, D.W. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 90, 3962-3966 (1997). (Pubitemid 27484049)
33. Kung, S.H. et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood 91, 784-790 (1998).
34. Margaritis, P. et al. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J. Clin. Invest. 113, 1025-1031 (2004). (Pubitemid 38544124)
35. Sambrano, G.R., Weiss, E.J., Zheng, Y.W., Huang, W. & Coughlin, S.R. Role of thrombin signaling in platelets in haemostasis and thrombosis. Nature 413, 74-78 (2001). (Pubitemid 32843490)
36. Falati, S., Gross, P., Merrill-Skoloff, G., Furie, B.C. & Furie, B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat. Med. 8, 1175-1181 (2002).